// App-Quantinova.ai

EP555 : OUTCOME OF RITUXIMAB-POLATUZUMAB-BENDAMUSTINE IN THE TREATMENT OF RELAPSED/ REFRACTORY HIGH GRADE LYMPHOMA AND TRANSFORMED HIGH GRADE LYMPHOMA – A MULTI-CENTRE ANALYSIS.

Researchers

Presenter

  • Lydia Sodhi

Principal Investigators

  • Andrew Robinson

  • Robert Spackman

  • Vita Ceidiene

  • Diana Lobo

  • Thomas McKerrell

  • Joseph Padayatty

  • Gavin Campbell

  • Sandra Young-Min

  • Mamatha Karanth

  • Isabel Lentell

  • Nicola Gill

  • Joel Cunningham

  • Andrew Hodson

  • Mahesh Prahladan

  • Shalal Sadullah

Medical Centers

  • Haemato oncology,West Suffolk Hospital,Bury St Edmunds,United Kingdom

  • Masters in Genomics project,University of Cambridge,Cambridge,United Kingdom

  • East Suffolk and North Essex NHS Foundation Trust,Ipswich,Regno Unito

  • Haemato oncology,James Paget Hospital,Great Yarmouth,United Kingdom

  • Haemato oncology,University of Cambridge/ East Suffolk and North Essex NHS foundation Trust,Cambridge,United Kingdom

  • Haematology,East Suffolk and North Essex NHS foundation Trust, Colchester,Colchester,United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Lymphomas

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Bendamustine

  • Rituximab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved